Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: Rationale and potential

Immunotherapy

Volumn 7, Issue 6, 2015, Pages 655-667

  Van De Ven, Koen ^a   Borst, Jannie ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

antibody; cancer; co inhibition; co stimulation; cytotoxic T cell; immunotherapy; ipilimumab; nivolumab; TNF receptor family

Indexed keywords

CD27 ANTIGEN; CD70 ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR; CD70 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NEUTRALIZING ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL EXPANSION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD27; ANTIGENS, CD70; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 84937677526     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.32     Document Type: Review

References (84)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
2. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
3. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
4. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165), 1432-1433 (2013).
5. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014-1022 (2013).
6. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415-421 (2013).
7. Kvistborg P, Philips D, Kelderman S et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6(254), 254ra128-254ra128 (2014).
8. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568-571 (2014).
9. Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014).
10. Aranda F, Vacchelli E, Eggermont A et al. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 3(1), e27297 (2014).
11. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3(12), 939-951 (2003).
12. Tan JKH, O'Neill HC. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J. Leukoc. Biol. 78(2), 319-324 (2005).
13. Bevan MJ. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4(8), 595-602 (2004).
14. Taraban VY, Rowley TF, Al-Shamkhani a. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 173(11), 6542-6546 (2004).
15. Tesselaar K, Xiao Y, Arens R et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170(1), 33-40 (2003).
16. Bullock TNJ, Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J. Immunol. 174(2), 710-717 (2005).
17. Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 178(3), 1564-1572 (2007).
18. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
19. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. 105(29), 10113-10118 (2008).
20. Bodmer J-L, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27(1), 19-26 (2002).
21. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3(9), 745-756 (2003).
22. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005).
23. Nolte MA, Van Olffen RW, Van Gisbergen KPJM, Van Lier RAW. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229(1), 216-231 (2009).
24. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17(3), 275-281 (2005).
25. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol. 10(6), 491-499 (1998).
26. Coquet JM, Ribot JC, B?ba?a N et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J. Exp. Med. 210(4), 715-728 (2013).
27. Hintzen RQ, Lens SMA, Koopman G, Pals ST, Spits H, van Lier RAW. CD70 represents the human ligand for CD27. Int. Immunol. 6(3), 477-480 (1994).
28. Laouar A, Haridas V, Vargas D et al. CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat. Immunol. 6(7), 698-706 (2005).
29. Iwamoto S, Iwai S, Tsujiyama K et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J. Immunol. 179(3), 1449-1457 (2007).
30. Krause P, Bruckner M, Uermösi C, Singer E, Groettrup M, Legler DF. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 113(11), 2451-2460 (2009).
31. Koenen HJPM, Fasse E, Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J. Immunol. 174(12), 7573-7583 (2005).
32. Van Lier RA, Borst J, Vroom TM et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol. 139(5), 1589-1596 (1987).
33. Goodwin RG, Alderson MR, Smith CA et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73(3), 447-456 (1993).
34. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1(5), 433-440 (2000).
35. Rowley TF, Al-Shamkhani A. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J. Immunol. 172(10), 6039-6046 (2004).
36. Schildknecht A, Miescher I, Yagita H, van den Broek M. Priming of CD8+ T cell responses by pathogens typically depends on CD70-mediated interactions with dendritic cells. Eur. J. Immunol. 37(3), 716-728 (2007).
37. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J. Exp. Med. 198(9), 1369-1380 (2003).
38. Peperzak V, Xiao Y, Veraar EAM, Borst J. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J. Clin. Invest. 120(1), 168-178 (2010).
39. Peperzak V, Veraar EAM, Xiao Y et al. CD8+ T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+ effector T cell pool. J. Immunol. 191(6), 3025-3036 (2013).
40. Xiao Y, Peperzak V, Keller AM, Borst J. CD27 instructs CD4+ T cells to provide help for the memory CD8+ T cell response after protein immunization. J. Immunol. 181(2), 1071-1082 (2008).
41. Van Gisbergen KPJM, Klarenbeek PL, Kragten NAM et al. The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. Immunity 35(1), 97-108 (2011).
42. Peperzak V, Veraar EAM, Keller AM, Xiao Y, Borst J. The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation. J. Immunol. 185(11), 6670-6678 (2010).
43. Van Oosterwijk MF, Juwana H, Arens R et al. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int. Immunol. 19(6), 713-718 (2007).
44. Dolfi D V, Boesteanu AC, Petrovas C, Xia D, Butz EA, Katsikis PD. Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells. J. Immunol. 180(5), 2912-2921 (2008).
45. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 115(10), 2618 (2005).
46. Carr JM, Carrasco MJ, Thaventhiran JED et al. CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proc. Natl Acad. Sci. USA 103(51), 19454-19459 (2006).
47. Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29(6), 934-946 (2008).
48. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005).
49. Arens R, Schepers K, Nolte MA et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J. Exp. Med. 199(11), 1595-1605 (2004).
50. Zwart W, Peperzak V, de Vries E et al. The invariant chain transports TNF family member CD70 to MHC class II compartments in dendritic cells. J. Cell Sci. 123(21), 3817-3827 (2010).
51. Keller AM, Groothuis TA, Veraar EAM et al. Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc. Natl Acad. Sci. USA 104(14), 5989-5994 (2007).
52. Pen JJ, De Keersmaecker B, Maenhout SK et al. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J. Immunol. 191(4), 1976-1983 (2013).
53. Soares H, Waechter H, Glaichenhaus N et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J. Exp. Med. 204(5), 1095-1106 (2007).
54. Coquet JM, Middendorp S, van der Horst G et al. The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity. Immunity 38(1), 53-65 (2013).
55. Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69(13), 5522-5530 (2009).
56. Melief CJM, van der Burg SH. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer. 8(5), 351-360 (2008).
57. Feau S, Garcia Z, Arens R, Yagita H, Borst J, Schoenberger SP. The CD4+ T-cell help signal is transmitted from APC to CD8+ T-cells via CD27-CD70 interactions. Nat. Commun. 3(5), 948 (2012).
58. Keller AM, Xiao Y, Peperzak V, Naik SH, Borst J. Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting. Blood 113(21), 5167-5175 (2009).
59. Arens R, Tesselaar K, Baars PA et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 15(5), 801-812 (2001).
60. Roberts DJ, Franklin NA, Kingeter LM et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J. Immunother. 33(8), 769-779 (2010).
61. Yamada A, Salama AD, Sho M et al. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J. Immunol. 174(3), 1357-1364 (2005).
62. Welten SPM, Redeker A, Franken KL et al. CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection. J. Virol. 87(12), 6851-6865 (2013).
63. Hendriks J, Xiao Y, Rossen JWA et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175(3), 1665-1676 (2005).
64. Wensveen FM, Unger P-PA, Kragten NAM et al. CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load. J. Immunol. 188(9), 4256-4267 (2012).
65. Mack DG, Lanham AM, Palmer BE, Maier LA, Fontenot AP. CD27 expression on CD4+ T cells differentiates effector from regulatory T cell subsets in the lung. J. Immunol. 182(11), 7317-7324 (2009).
66. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 72(14), 3664-3676 (2012).
67. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, van Oers MH, van Lier RA. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat. Immunol. 4(1), 49-54 (2003).
68. Arens R, Baars PA, Jak M et al. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation. J. Immunol. 174(10), 5915-5920 (2005).
69. Penaloza-MacMaster P, Rasheed AU, Iyer SS, Yagita H, Blazar BR, Ahmed R. Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J. Virol. 85(13), 6168-6174 (2011).
70. Yang Z-Z, Grote DM, Xiu B et al. TGF-? upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 28(9), 1872-1884 (2014).
71. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J. Immunol. 172(12), 7432-7441 (2004).
72. Vossen MTM, Matmati M, Hertoghs KML et al. CD27 defines phenotypically and functionally different human NK cell subsets. J. Immunol. 180(6), 3739-3745 (2008).
73. Takeda K, Oshima H, Hayakawa Y et al. CD27-mediated activation of murine NK cells. J. Immunol. 164(4), 1741-1745 (2000).
74. Sakanishi T, Yagita H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem. Biophys. Res. Commun. 393(4), 829-835 (2010).
75. Kelly JM, Darcy PK, Markby JL et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3(1), 83-90 (2002).
76. French RR, Taraban VY, Crowther GR et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109(11), 4810-4815 (2007).
77. Vitale LA, He L-Z, Thomas LJ et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin. Cancer Res. 18(14), 3812-3821 (2012).
78. He L-Z, Prostak N, Thomas LJ et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J. Immunol. 191(8), 4174-4183 (2013).
79. Hünig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat. Rev. Immunol. 12(5), 317-318 (2012).
80. Van Montfrans JM, Hoepelman AIM, Otto S et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J. Allergy Clin. Immunol. 129(3), 787-793.e6 (2012).
81. Salzer E, Daschkey S, Choo S et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 98(3), 473-478 (2013).
82. Ansell SM, Northfelt DW, Flinn I et al. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. J. Clin. Oncol. 32(5), Suppl. abstract 3024 (2014).
83. Neyns B, Wilgenhof S, Van Nuffel AMT et al. A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). In: ASCO Annual Meeting Proceedings 2519 (2011).
84. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).